The purpose of this study is to find out about the safety and effectiveness of monthly study treatment with abelacimab (hereafter referred to as the study drug) in subjects with atrial fibrillation/flutter (AF) who are not treated with oral anticoagulants because they have been deemed by their responsible physicians or by their own decision to be unsuitable for currently available oral blood thinners.